DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00349193 (ClinicalTrials.gov)	March 2005	26/6/2006	A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod	A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects	Relapsing Remitting Multiple Sclerosis	Drug: laquinimod 0.3;Drug: laquinimod 0.6;Other: Placebo	Teva Pharmaceutical Industries	NULL	Completed	18 Years	50 Years	Both	306	Phase 2	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00349193
(ClinicalTrials.gov)

March 2005

26/6/2006

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

A Multinational, Multicenter Randomized Double-Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate the Efficacy, Tolerability and Safety of Two Doses of, Oral Laquinimod in Relapsing Remitting (R-R) Multiple Sclerosis (MS) Subjects

Relapsing Remitting Multiple Sclerosis

Drug: laquinimod 0.3;Drug: laquinimod 0.6;Other: Placebo

Teva Pharmaceutical Industries

NULL

Completed

18 Years

50 Years

Both

306

Phase 2

Italy